Innate Pharma Regains Its Rights on CD123 Targeting ANKET ® and Announces Sanofi's Intention to Make a Strategic Investment in the Company




Innate Pharma Regains Its Rights on CD123 Targeting ANKET ® and Announces Sanofi's Intention to Make a Strategic Investment in the Company


Leave a Reply

Your email address will not be published. Required fields are marked *